Ternary Therapeutics Secures £3.6M to Advance AI-Driven Molecular Glue Drug Discovery Platform
核心洞察
Ternary Therapeutics (搜索) raised £3.6 million in seed funding to scale its AI-powered platform for designing molecular glue drugs that force proteins to bind together for therapeutic purposes.
The London-based company combines physics-informed AI, molecular dynamics modeling, and laboratory testing to systematically design molecular glues (搜索) rather than relying on accidental discovery.
The platform has already generated a preclinical pipeline targeting inflammatory diseases (搜索) and secured multiple research collaborations with pharmaceutical and biotechnology companies.
Ternary Therapeutics (搜索) has raised £3.6 million in seed funding to advance its artificial intelligence-powered platform for designing molecular glue drugs, positioning the London-based startup in the competitive targeted protein degradation space. The financing was led by European venture firm daphni (搜索), with participation from Pace Ventures (搜索), i&i Biotech Fund (搜索), and the UK Innovation & Science Seed Fund managed by Future Planet Capital (搜索).
Founded in November 2024, Ternary has developed an integrated platform that combines artificial intelligence, physics-based modeling, and laboratory testing to design molecular glues (搜索) systematically rather than through serendipitous discovery. Molecular glues are small drug molecules that force two proteins inside a cell to stick together, potentially switching off harmful proteins or restoring lost cellular function.
Platform Technology and Approach
The company's software predicts how proteins move and interact at the atomic level, then proposes small molecules that could bring two specific proteins together in a controlled manner. These computational predictions undergo rapid laboratory testing, with results fed back into the system to improve subsequent design cycles. This creates what the company describes as a closed loop between computation and experiment that replaces chance with engineering.
"For decades, molecular glues (搜索) have been one of the most powerful ideas in drug discovery, but also one of the least predictable," said Dr. Chris Tame, co-founder and chief executive of Ternary Therapeutics (搜索). "We have shown that by combining physics-informed AI with tight experimental feedback, we can design these molecules intentionally rather than waiting to discover them by luck."
Clinical Pipeline and Partnerships
The platform has already produced a pipeline of preclinical drug candidates aimed at inflammatory diseases (搜索) where existing treatments are limited or ineffective. Ternary's particular emphasis is on inflammation and neuroinflammation, areas where many important targets remain outside the reach of standard small-molecule approaches. The company has also signed multiple research collaborations with pharmaceutical and specialist biotechnology companies.
Strategic Leadership Addition
As part of its expansion, Ternary appointed Dr. Ian Taylor to its board of directors. Dr. Taylor recently retired as president of research and development at Arvinas, where he oversaw six Investigational New Drug submissions during his nine-year tenure. One of those programs, the estrogen receptor (搜索) PROTAC (搜索) vepdegestrant, is currently under review by the US Food and Drug Administration and could become the first approved therapy of its kind.
Dr. Taylor earned his PhD in molecular biology and genetics from Harvard University and completed postdoctoral research under Nobel laureate Harold Varmus. He previously held senior roles at Pfizer Oncology (搜索) and Bayer Pharmaceuticals.
Investment Rationale and Market Context
"Designing molecular glues (搜索) predictably is one of the hardest challenges in modern drug discovery. It requires deep expertise across machine learning, physics and experimental biology," said Cristian Pinto, investor at daphni (搜索). "Ternary has built a platform that integrates all three in a disciplined and scalable way."
The investment follows the recent launch of Daphni (搜索) Blue, a €260 million fund focused on science-led deep technology companies addressing major societal challenges. The financing puts Ternary among European companies entering the closely watched targeted protein degradation space, though the sector has faced clinical and commercial setbacks alongside its promise.
Future Development Plans
The new capital will enable Ternary to expand its scientific and computational teams and advance lead programs toward clinical development. The company operates from London with laboratory space at Stevenage Bioscience Catalyst, positioning itself to leverage both computational capabilities and experimental validation in its drug discovery efforts.